Navigation Links
183 New Medicines in Development for Diabetes
Date:12/11/2009

WASHINGTON, Dec. 11 /PRNewswire-USNewswire/ -- Nabe News in Brooklyn, New York recently reported that 183 new medicines are in development to fight diabetes. The report details a record number of drugs for this chronic disease currently in human clinical trials and awaiting approval by the U.S. Food and Drug Administration. The report was released by America's pharmaceutical research and biotechnology companies (PhRMA).

Diabetics do not produce or properly use insulin, a hormone needed to convert sugar, starches and other food into energy. This chronic disease affects 24.7 percent of Brooklyn's adults, or 449,900 people, according to the Centers for Disease Control and Prevention.

"This killer thrives in communities like ours, where poverty and fast food are prevalent," said Dr. Richard Becker, president and CEO of the Brooklyn Hospital Center.

Rep. Edolphus Towns, who suffers from diabetes, attended the event at the Brooklyn Hospital Center as well.

"Developing new drugs to treat diabetes here in New York City will help address one of the major diseases affecting our community," the lawmaker said. Of New York's five boroughs, Brooklyn has the second highest rate of diabetes.

According to PhRMA, one of the drugs in development significantly improves long-term blood sugar control and targets the dysfunction of pancreas cells, a dysfunction that causes high sugar level in type 2 diabetes, the most common form of the disease. Another medicine in development stimulates the release of insulin only when glucose levels become too high and by suppressing appetite in patients with type 2 diabetes.

"The medicines now in the research pipelines are contributing significantly to the incredible progress made by America's pharmaceutical research and biotechnology companies in developing new treatments for diabetes and related conditions," said Ed Belkin, PhRMA vice president for communications and public affairs.

To read the full story, go to the Nabe News web site.

SOURCE Pharmaceutical Research and Manufacturers of America


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. 92 Medicines and Vaccines now in Development for HIV/AIDS
2. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
3. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
6. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
7. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. More Than 300 New Medicines Being Developed for Mental Illnesses
10. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
11. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
Breaking Medicine News(10 mins):